drugset / Trial / NCT04993040

A PK Study of Oraxol in Breast Cancer Patients

NCT04993040

Phase 1 Completed 24 enrolled Athenex, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, single-arm PK study in approximately 24 breast cancer patients for whom paclitaxel treatment is indicated.

Timeline

Start
2019-04-22
Primary completion
2019-12-09
Completion
2020-12-09

Drugs

EvaluationDrugModalityDoseRoute
Subject HM30181AK Unknown
Subject Paclitaxel Small molecule Oral

Indications